title: Sympathetic neuroimaging.
abstract: Sympathetic neuroimaging provides an important supplement to physiological, neurochemical, and neuropharmacological approaches in the evaluation of patients with clinical autonomic disorders. Almost all sympathetic neuroimaging to date has involved visualization of noradrenergic innervation in the left ventricular myocardium. Single-photon emission computed tomography (SPECT) scanning after injection of the sympathomimetic amine (123)I-metaiodobenzylguanidine ((123)I-MIBG) constitutes by far the most commonly used means worldwide to assess cardiac sympathetic innervation. Based on heart:mediastinum ratios of (123)I-MIBG-derived radioactivity, decreased uptake, increased washout, or both have been reported in many disorders and relate to diagnosis and prognosis. Cardiac sympathetic neuroimaging and postmortem neuropathological findings have linked α-synucleinopathy with noradrenergic denervation in Lewy body diseases. Especially because of the utility of cardiac sympathetic neuroimaging in distinguishing Parkinson disease from multiple system atrophy in patients with clinical evidence of central neurodegeneration and orthostatic hypotension, sympathetic neuroimaging seems a valuable addition to physiological, neuropharmacological, and neurochemical approaches in the diagnostic evaluation of selected patients with autonomic and neurodegenerative disorders.
authors.affiliation: Clinical Neurocardiology Section, Clinical Neurosciences Program, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. Electronic address: goldsteind@ninds.nih.gov.
authors.forename: David S
authors.initials: DS
authors.lastname: Goldstein
mesh_terms: D000818:Animals; D001342:Autonomic Nervous System Diseases / Q000175:diagnosis*; D006801:Humans; D059906:Neuroimaging; D013564:Sympathetic Nervous System / Q000033:anatomy & histology*
keywords: MIBG; PET; Sympathetic; fluorodopamine; neuroimaging